SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, will be sending Company representatives on August 2-3, 2017, to attend the 69th AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego, California.

Representatives from the Company’s science and marketing divisions have visits scheduled with executives of potential clients to discuss sales of Co-Diagnostics’ technology and design platform in the field of molecular biology. As described on its website, AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. The annual expo provides industry leaders the chance to introduce new products in the field of laboratory medicine, and opportunities to meet and build relationships with potential customers and partners.

Co-Diagnostics CEO Dwight Egan, who will be among those in attendance, commented, “We are enthusiastic about the chance to introduce the unique multiplexing capabilities of our CoPrimer™ technology in person to so many influential organizations in our sector, as well as the value that our test design platform could add to their existing operations. We would invite any other fellow attendees who have been following our progress and who might be interested in connecting during the expo to reach out at the email address at the end of this release.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer:

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170802006061/en/

Co-Diagnostics
Andrew Benson, 801-438-1036
info@codiagnostics.com